Having trouble viewing email? VIEW IN WEB BROWSER»
FDA Indication for MyoSure
The MyoSure® system sees continued success with its newest indication for retained products of conception (RPOC)

Retained products of conception (RPOC) is non-viable pregnancy tissue that has not passed due to:
- Failed expectant management.
- Post treatment of miscarriage.
- Term delivery.
Traditional D&C is the most common treatment for RPOC,
but the data shows:
- Increased risk of perforation, infection and bleeding.1
- 19% incidence of adhesion formation after D&C.2
- Up to 32% incidence of adhesion formation after multiple D&C procedures.2
21% of women with RPOC also have uterine abnormalities that would benefit from hysteroscopic removal.3

The MyoSure system is a solution for the removal of RPOC:
- Remove only the targeted tissue.
- Reduced risk of damage to healthy tissue.
- Direct visualization for confirmation of removal.
Identify additional undiagnosed uterine abnormalities for removal




Dr. Robert Zurawin’s paper,

  A Novel Technique for Resection of Retained Products of Conception using a Hysteroscopic Morcellation Device
  featuring the MyoSure device, was awarded Best Scientific
Paper- Gynecology at the
2015 SLS Annual Meeting.


Watch Dr. Zurawin perform
the procedure.


  Visit us at
Minimally Invasive Surgery Week 2015
SLS Annual Meeting &
Endo Expo
New York, New York, USA

September 2-5, 2015

Booth #104



1. Sadan O, et al. Role of sonography in the diagnosis of retained products of conception. J Ultrasound Med 2004; 23:371-74. 2. Friedler S, Margaloioth EJ, Kafka I, Yaffe H. Incidence of post-abortion intra-uterine adhesions evaluated by hysteroscopy-a-prospective study. Hum Reprod. 1993;8:442-444 3. Cohen SB, et al. Hysteroscopy may be the method of choice for management of residual trophoblastic tissue. J Am Assoc Gynecol Laparosc. 2001; 8:199-202. 4. Harpham M, Abbott J. Use of a hysteroscopic morcellator to resect miscarriage in a woman with recurrent Asherman syndrome. J Minim Invasive Gynecol. Published on-line May 24, 2014. DOI: http://dx.doi.org/10.1016/j.jmig.2014.05.006

EMB-00685-001 Rev. 001 ©2015 Hologic, Inc. Hologic and MyoSure are trademarks or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.